PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Genolution has layered RNAi green-bio and beauty businesses on top of its molecular diagnostics core, posting two consecutive quarters of net profit attributable to owners in 2026 even as operating losses continued for a fourth straight year.
2025 consolidated revenue rose year-on-year to KRW 9.404 billion, but operating losses persisted for a fourth consecutive year.
Net income attributable to owners turned positive for two consecutive quarters in 1Q and 2Q 2026.
The largest shareholder changed from Hoil Biomed to founder-CEO Kim Ki-ok, reshaping the governance structure.
Honeygard-R, the world's first commercialized bee gene therapy, was designated a government innovation product, opening public-procurement channels.
Shareholders' equity has declined for four straight years while operating cash outflow has widened, signaling weaker financial buffers.
Founded in 2006, Genolution operates an in-vitro diagnostics and green-bio business built around nucleic-acid extraction reagents and equipment, an RNA interference (RNAi)-based green-bio business, and a beauty device business.
The diagnostics segment is split between extraction reagents and automated extraction instruments, with reagents used to isolate DNA and RNA from blood, serum, and urine samples to detect pathogens.
In 2020, driven by COVID-19 testing demand, the company recorded revenue of KRW 85.3 billion and operating profit of KRW 54.0 billion, with exports accounting for 93% of sales and extraction reagents, equipment, and RNAi making up 75%, 24%, and 1% of exports respectively.
As of 1Q 2026, revenue mix was led by resale of Bio-Rad and other products at 54%, followed by proprietary extraction reagents at 34%, the RNAi business at 9%, equipment parts and genomic analysis at 2%, and other items at 1%, indicating a rising share of distributed goods.
In green bio, the company centers on Honeygard-R, the world's first commercialized gene therapy for bee sacbrood disease, alongside RNAi crop-protection agents targeting plant viruses and pests, and molecular diagnostic solutions for avian influenza and African swine fever.
The beauty segment is run through the home-shopping-oriented premium device 'Ambeulpretti' and plasma-beauty subsidiary Bianble Biotech, which recently hired a distribution and marketing specialist to expand into owned e-commerce and overseas channels.
On governance, founder Kim Ki-ok and his daughter Kim Min-yi serve as co-CEOs, with Kim Ki-ok leading the extraction business and Kim Min-yi leading RNA research.
The customer base spans domestic and overseas diagnostic labs, research institutions, and agricultural/animal-health partners, and the company has also pursued OEM contract-manufacturing deals with molecular diagnostics firms to expand domestic clinical references.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.9B | -₩1.7B | −58.8% |
| 2025Q3 | ₩2.1B | -₩2.4B | −117.9% |
| 2025Q4 | ₩2.4B | -₩2B | −84.8% |
| 2026Q1 | ₩2.5B | -₩1.4B | −55.6% |
| 2026Q2 | ₩3.1B | -₩1.6B | −51.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩38.1B | ₩14.7B | ₩14.6B | 38.7% | 15.4% | 20.9% |
| 2023 | ₩9.8B | -₩7.1B | -₩5.5B | −72.6% | −6.3% | 29.4% |
| 2024 | ₩7.1B | -₩9.2B | -₩6.8B | −128.4% | −8.5% | 32.4% |
| 2025 | ₩9.4B | -₩8.6B | -₩11.6B | −91.9% | −17.0% | 38.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue in 2025 was KRW 9.404 billion, up 31.8% from KRW 7.136 billion in 2024, while the operating loss narrowed 5.7% year-on-year to KRW 8.642 billion from KRW 9.164 billion. However, net loss attributable to owners widened to KRW 11.643 billion from KRW 6.826 billion, an increase of 70.6%.
Operating margin, which had reached 38.7% in 2022 on pandemic-driven demand, remained deeply negative at -72.6% in 2023, -128.4% in 2024, and -91.9% in 2025.
Quarterly results show losses concentrated in 3Q 2025 (revenue KRW 2.069 billion, operating loss KRW 2.440 billion, net loss attributable to owners KRW 0.918 billion) and 4Q 2025 (revenue KRW 2.385 billion, operating loss KRW 2.022 billion, net loss attributable to owners KRW 5.115 billion).
By contrast, 1Q 2026 (revenue KRW 2.486 billion, operating loss KRW 1.382 billion, net income attributable to owners KRW 0.597 billion) and 2Q 2026 (revenue KRW 3.092 billion, operating loss KRW 1.594 billion, net income attributable to owners KRW 0.775 billion) each posted positive net income attributable to owners for two consecutive quarters.
Still, cumulative net income attributable to owners over the trailing four quarters (3Q 2025 through 2Q 2026) was negative KRW 4.661 billion, indicating the quarterly improvement has not yet translated into a full-year swing to profit.
Operating cash flow, which was a positive KRW 13.551 billion in 2022, turned negative at KRW 1.136 billion in 2023, KRW 1.433 billion in 2024, and widened to KRW 7.012 billion in outflow in 2025.
Shareholders' equity fell for four consecutive years from KRW 94.699 billion in 2022 to KRW 67.879 billion in 2025, while the debt ratio rose from 20.9% to 38.2% over the same period.
The molecular diagnostics market has entered a normalization phase after the COVID-19 boom, with the global nucleic-acid extraction market projected to reach USD 9.2 billion by 2027, growing about 8% annually.
In green bio, the RNAi-based crop-protection market is emerging rapidly: Insight Ace Analytic estimated the market at USD 1.2 billion in 2024, growing at a 14.2% CAGR to USD 4.6 billion by 2034, while Research and Markets projected growth from USD 1.72 billion in 2025 to USD 3.04 billion by 2031 — figures that differ by methodology but agree on a high-growth trajectory.
The adjacent wastewater surveillance market is also expected to grow from USD 0.88 billion in 2025 to USD 1.22 billion by 2030, according to MarketsandMarkets.
South Korea's government is expanding policy support for chemical-pesticide alternatives through its sixth five-year eco-friendly agriculture promotion plan covering 2026-2030, creating a favorable policy backdrop for RNA-based pesticide commercialization.
Competitively, large global diagnostics companies dominate the nucleic-acid extraction market, while Genolution positions itself as one of a small number of domestic firms with localized automated extraction equipment and reagent technology.
The RNAi green-bio field remains in an early commercialization stage with limited competition, though the United States has already approved and deployed RNAi-based insecticides and China has established registration guidelines, signaling the start of global commercialization competition.
The company is pursuing cost reductions through magnetic-bead-related patent filings and continues to sell into more than ten countries in its RNAi business, leveraging its RNA synthesis capabilities.
It has also indicated it is pursuing revenue growth and profitability improvement by shifting toward kilogram-scale mass production.
In green bio, Honeygard-R was designated a government innovation product in April 2026, enabling sole-source contracts with public institutions and local governments for the next three years and raising expectations for expanded public-procurement channels.
The RNA crop-protection pipeline has expanded with patents targeting tomato spotted wilt virus (TSWV), followed by cucumber mosaic virus (CMV) and broad bean wilt virus 2 (BBWV2), building out a comprehensive protection lineup for horticultural crops.
The company has also extended into forestry, filing a domestic RNAi patent for controlling pine wilt nematode disease. Beauty subsidiary Bianble Biotech has hired dedicated sales personnel to expand its distribution beyond home shopping into owned e-commerce and overseas channels.
Following the 1Q 2026 earnings improvement and patent achievements, the company stated it aims to maximize synergy under the co-CEO structure to drive core pipeline results and enhance shareholder value.
On a trailing four-quarter basis, net losses attributable to owners have persisted, putting the price-to-earnings ratio in a range where the metric carries limited meaning. The price-to-book ratio, on an in-house calculation basis, sits below 1x, implying the stock trades at a discount to net asset value.
Compared with its five-year average price-to-book ratio, the current level sits below that historical average. The company has not paid dividends in recent years, limiting its appeal from a dividend-yield perspective.
That said, the return to quarterly net profit for two consecutive quarters in 2026 could become a new variable in future valuation discussions.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Net income attributable to owners turned positive for two consecutive quarters in 1Q and 2Q 2026. Revenue has also risen for four straight quarters since bottoming in 3Q 2025. Operating profit itself, however, remains in loss territory, warranting further scrutiny of earnings quality.
Honeygard-R, the world's first commercialized bee therapy, was designated a government innovation product, opening public-procurement channels. The RNA crop-protection portfolio is also expanding with patents targeting multiple viruses including TSWV, CMV, and BBWV2. The global RNAi crop-protection market's double-digit growth rate provides a favorable backdrop.
Founder-CEO Kim Ki-ok acquired all remaining shares held by former largest shareholder Hoil Biomed, simplifying the governance structure. Co-CEO Kim Min-yi has also continued to purchase treasury-market shares this year. The expansion of management's shareholding can be interpreted as a sign of committed ownership.
After returning to profit in 2022, the company posted operating losses for three consecutive years from 2023 to 2025, with operating margin at -91.9% in 2025. Since the pandemic-driven demand faded, the core business has not recovered profitability on its own. New businesses' revenue contribution also remains limited so far.
Operating cash flow has been negative for three straight years since 2023, widening to roughly KRW 7 billion of outflow in 2025. Shareholders' equity has declined for four consecutive years, from KRW 94.7 billion in 2022 to KRW 67.9 billion in 2025. The debt ratio rose over the same period from 20.9% to 38.2%.
The RNA crop-protection and beauty businesses remain largely at the patent-filing or approval stage, leaving the timing of meaningful revenue contribution uncertain. In the 1Q 2026 revenue mix, resale of Bio-Rad and other distributed products still exceeded proprietary product sales. Additional time may be needed before new businesses convert into substantial revenue.
Accumulated operating losses and negative operating cash flow could necessitate future capital raises or additional financing. The four-year decline in shareholders' equity also suggests a weakening financial buffer.
There have been frequent changes in the shareholding structure over the past year, including the shift of the largest-shareholder position from Hoil Biomed to CEO Kim Ki-ok. Continued share transfers among related parties could affect market confidence or ownership stability going forward.
RNA-based crop-protection agents and animal medicines require separate country-specific approval and registration processes before commercial sale, while the beauty business's reliance on channels such as home shopping can increase revenue volatility.
The possibility that patent filings do not translate into actual commercialization or revenue cannot be ruled out.
Check 3Q revenue, operating profit, and net income trends to see whether the 1H 2026 return to net profit continues.
Verify whether and to what scale sole-source contracts with local governments and public institutions materialize following the innovation-product designation, to gauge green-bio revenue contribution.
Confirm whether the TSWV, CMV, and BBWV2 patent pipeline advances into actual field trials or licensing agreements.
Assess whether the beauty business's revenue structure shifts as it expands into owned e-commerce and overseas channels.
Any further share purchases or sales by the largest shareholder and related parties serve as a reference for assessing management commitment and governance stability.
Genolution has pursued diversification by layering RNAi green-bio and beauty businesses on top of its molecular diagnostics cash-cow business since the end of the COVID-19 boom.
Consolidated revenue in 2025 rose year-on-year to KRW 9.404 billion, but the operating loss persisted for a fourth consecutive year and the net loss attributable to owners actually widened.
In 2026, net income attributable to owners turned positive for two consecutive quarters in 1Q and 2Q, yet operating profit itself remained negative and the trailing four-quarter cumulative figure still shows a net loss.
On the balance sheet, shareholders' equity has fallen for four straight years and the debt ratio has risen, while operating cash outflow has widened — signals of weakening cash-generation capacity.
On the other hand, the green-bio growth narrative continues to build, anchored by the world's first commercialized bee gene therapy, an expanding portfolio of RNA crop-protection patents, and expected benefits from government policy, alongside strengthened management accountability through increased insider shareholding.
Before forming any judgment, it is worth tracking the durability of the quarterly return to profit, the timing of actual revenue contribution from new businesses, and whether cash flow improves.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.